{"id":6443,"date":"2022-08-04T17:35:24","date_gmt":"2022-08-04T09:35:24","guid":{"rendered":"https:\/\/www.excelsiormedical.com.tw\/?p=6443"},"modified":"2023-01-09T17:05:19","modified_gmt":"2023-01-09T09:05:19","slug":"the-board-of-directors-release-the-prohibition-on-managers-from-participation-in-competition-businesses","status":"publish","type":"post","link":"https:\/\/www.excelsiormedical.com.tw\/en\/investors\/the-board-of-directors-release-the-prohibition-on-managers-from-participation-in-competition-businesses\/","title":{"rendered":"The Board of Directors release the prohibition on managers from participation in competition businesses."},"content":{"rendered":"

 <\/p>\n\n\n\n\n\n\n
SEQ_NO<\/td>\n\u00a03<\/td>\nDate of announcement<\/td>\n2022\/08\/04<\/td>\nTime of announcement<\/td>\n17:34:08<\/td>\n<\/tr>\n
Subject<\/td>\n\n
The Board of Directors release the prohibition on\r\nmanagers from participation in competition businesses.<\/pre>\n<\/td>\n<\/tr>\n
Date of events<\/td>\n2022\/08\/04<\/td>\nTo which item it meets<\/td>\nparagraph 21<\/td>\n<\/tr>\n
Statement<\/td>\n\n
1.Date of the board of directors resolution: 2022\/08\/04\r\n2.Name and title of the managerial officer with \r\n  permission to engage in competitive conduct:\r\n  Chou Cheng-Hsiao\uff0cCorporate Governance Officer.\r\n3.Items of competitive conduct in which the officer is \r\n  permitted to engage: Acting in the business of the \r\n  same or similar nature of a company as thatof the \r\n  company.\r\n4.Period of permission to engage in the competitive \r\n  conduct: For the duration of being employed as a \r\n  manager of the Company.\r\n5.Circumstances of the resolution (please describe \r\n  the results of voting in accordance with Article 32 \r\n  of the Company Act):\r\n  All directors present at the meeting pass unanimously.\r\n6.If the permitted competitive conduct belongs to the \r\n  operator of a mainland China area enterprise, the name\r\n  and title of the managerial officer (if it is not the \r\n  operator of a mainland China area enterprise, please \r\n  enter \u201cN\/A\u201d below):\r\n  Chou Cheng-Hsiao\uff0cCorporate Governance Officer.\r\n7.Company name of the mainland China area enterprise \r\n  and the officer's position in the enterprise:\r\n  Supervisor of SinoExcelsior Investment Incorporation.\r\n8.Address of the mainland China area enterprise:\r\n  SinoExcelsior Investment Incorporation address:\r\n  Room 301-2, No.1089, Kang Ning Lu, Shanghai Shi, China.\r\n9.Operations of the mainland China area enterprise:\r\n  enterprise management consulting, business information\r\n  consulting,technical consulting and technical services\r\n  in the professional field of medical technology (except\r\n  for the development and application of human stem \r\n  cells,gene diagnosis and treatment technology), and \r\n  wholesale of cosmetics , import and export, beauty-\r\n  related shop, hair-related shop(limited to branch \r\n  operations).\r\n10.Impact on the company's finance and business:None.\r\n11.If the managerial officer has invested in the mainland\r\n   China area enterprise, the monetary amount of the \r\n   investment and the officer's shareholding ratio:None.\r\n12.Any other matters that need to be specified:None.<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"
  SEQ_NO \u00a03 Date of announcement 2022\/08\/04 Time of announcement 17:34:08 Subject The Board of Directors release the prohibition on managers from participation in competition businesses. Date of events 2022\/08\/04 To which item it meets paragraph 21 Statement 1.Date of the board of directors resolution: 2022\/08\/04 2.Name and title of the managerial officer with permission …<\/p>\n
  The Board of Directors release the prohibition on managers from participation in competition businesses.<\/span> Read More »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[72,102],"tags":[],"class_list":["post-6443","post","type-post","status-publish","format-standard","hentry","category-investors","category-material-information"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=6443"}],"version-history":[{"count":8,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6443\/revisions"}],"predecessor-version":[{"id":6452,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6443\/revisions\/6452"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=6443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=6443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=6443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}